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Abstract  
 
This patient is a 9-year-old girl who had a diagnosis of tuberous sclerosis complex 
(TSC), based on clinical features (facial angiofibromas, hypomelanotic macules and 
cortical dysplasia). She had a swollen left ring finger, which has become more evident 
as she grew older. The swelling has been proportionally increasing with her size. It 
has not limited her function.  
 
TSC is a neurogenetic condition caused by mutations in the tumour suppressor genes 
TSC1 and TSC2. [1,2] Mutations in either TSC1 or TSC2 lead to overactivation of the 
mTORC 1 pathway and relatively uncontrolled cell growth. [3] This, in turn, causes 
growth of hamartomas in various organs. Bone lesions are often incidental findings on 
X-rays or CT scans of patients with TSC but these lesions are generally over-looked 
as it is assumed that they are clinically insignificant, asymptomatic and nonspecific. 
However, they can cause significant pain and physical disability, particularly when 
there is spinal involvement. Their natural history is unknown as not many patients with 
TSC are screened, or receive routine follow-up for bone lesions. [4] We do not routinely 
screen for bone lesions and it is not recommended by the international consensus 
guidelines for TSC management. It would not be practically possible to routinely 
screen all patients with TSC for these lesions because they can occur in any bone, as 
illustrated in this case. However, in our practice, we image or X-ray patients if they are 
symptomatic. mTOR inhibitors, such as rapamycin, have been shown to be effective 
in halting the growth of bone lesions and improving function. [5] of mTOR inhibitors 
may alleviate the patient’s symptoms. However, currently mTOR inhibitors do not have 
licensing approval in the UK for this purpose (figures 1 and 2).  
 
 Figure 1: photo of both hands which shows swelling of the left ring finger.  
 
 Figure 2: x-ray shows a combination of diffuse soft tissue thickening and bony 
thickening and sclerosis of the shafts of the middle and proximal phalanges of the left 
ring finger.    
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